Literature DB >> 3015659

Opiate-induced seizures: a study of mu and delta specific mechanisms.

O C Snead.   

Abstract

Two groups of experiments were conducted to determine if morphine- and enkephalin-induced seizures are specifically mediated by the mu and delta receptor, respectively. In the first experiments, designed to assess the ontogeny of mu- or delta-seizures, rats from 6 h to 85 days of age received implanted cortical and depth electrodes as well as an indwelling cannula in the lateral ventricle. Various amounts of the mu-receptor agonists, morphine and morphiceptin, and the delta agonists, D-Ala2-D-Leu5-enkephalin (DADL) and Tyr-D-Ser-Gly-Phe-Leu-Thr (DSLET), were then administered intracerebroventricularly (icv) with continuous EEG monitoring. The second experiments entailed use of the nonspecific opiate antagonist, naloxone, as well as the specific delta antagonist, ICI 154,129, against seizures induced by icv-administered morphine, morphiceptin, DADL, or DSLET. Both morphine and morphiceptin produced electrical seizure activity in rats as young as 5 days after birth. The drugs produced similar seizure activity in terms of electrical morphology, observed behavior, ontogeny, threshold dose, and reversibility with small doses of naloxone. In the pharmacologic experiments, icv naloxone blocked all opiate-induced seizures. ICI 154,129 blocked DSLET seizure, had little effect on enkephalin or DADL seizures, and no effect on morphine or morphiceptin seizures. These data indicate that DSLET seizures are delta-specific but that all other opiate-induced seizures studied may involve multiple opiate receptor-mediated mechanisms.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3015659     DOI: 10.1016/0014-4886(86)90195-0

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  6 in total

1.  Validation of a preclinical spinal safety model: effects of intrathecal morphine in the neonatal rat.

Authors:  B David Westin; Suellen M Walker; Ronald Deumens; Marjorie Grafe; Tony L Yaksh
Journal:  Anesthesiology       Date:  2010-07       Impact factor: 7.892

2.  Morphine metabolite pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates.

Authors:  Jeroen W B Peters; Brian J Anderson; Sinno H P Simons; Donald R A Uges; Dick Tibboel
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 3.  Post-translational Modifications of Opioid Receptors.

Authors:  Mariana Lemos Duarte; Lakshmi A Devi
Journal:  Trends Neurosci       Date:  2020-04-16       Impact factor: 13.837

4.  Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects.

Authors:  Emily M Jutkiewicz; Mary M Torregrossa; Katarzyna Sobczyk-Kojiro; Henry I Mosberg; John E Folk; Kenner C Rice; Stanley J Watson; James H Woods
Journal:  Eur J Pharmacol       Date:  2006-01-25       Impact factor: 4.432

Review 5.  Molecular Targets of Cannabidiol in Neurological Disorders.

Authors:  Clementino Ibeas Bih; Tong Chen; Alistair V W Nunn; Michaël Bazelot; Mark Dallas; Benjamin J Whalley
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

6.  Refinement of a chronic cranial window implant in the rat for longitudinal in vivo two-photon fluorescence microscopy of neurovascular function.

Authors:  Margaret M Koletar; Adrienne Dorr; Mary E Brown; JoAnne McLaurin; Bojana Stefanovic
Journal:  Sci Rep       Date:  2019-04-02       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.